Intranasal Treatments for Children With Sleep-Disordered Breathing

Read full text
Authors: Gillian M. Nixon, Deborah J. Anderson, Alice Baker, A. Fiona Davidson, Amanda Griffiths, Anneke Grobler, Gideon D. Pinczower, Joanne Rimmer, Elizabeth Rose, Chris J. Selman, C. J. Simpson, Moya Vandeleur
+1 more Kirsten P. Perrett
Cited by: 4
References: 40

Abstract

Importance: Symptoms of obstructive sleep apnea are common in childhood and associated with significant comorbidity. Surgical treatment with adenotonsillectomy is first-line treatment but medical treatments show potential to improve symptoms and reduce the need for surgery. Objective: To determine the efficacy of 6 weeks of intranasal steroid (INS) compared with saline in children with obstructive sleep-disordered breathing (OSDB) with persistent symptoms after a 6-week intranasal saline run-in. Design, Setting, and Participants: This was a double-blind, placebo-controlled, randomized clinical trial involving specialist clinic waitlists at 2 sites in Australia. Included were children aged 3 to 12 years. Study data were analyzed from January to June 2025. Interventions: All children received once-daily intranasal saline for 6 weeks (run-in). Those with persisting symptoms (SDB score ≥-1) were randomized to either once-daily intranasal mometasone furoate, 50 µg, (INS) or continued saline for a further 6 weeks. Main Outcomes and Measures: The primary outcome was symptom resolution (SDB score

Fields of Study & Subjects

Obstructive Sleep Apnea Research Neuroscience of respiration and sleep Nasal Surgery and Airway Studies

Publication details

Journal / source
Archives of Pediatrics and Adolescent Medicine
Publisher
American Medical Association (AMA)
Volume
180
Issue
3
Pages
240–240
Publication date
20 January 2026
Language
EN